Pharma firm cuts prices of hypertension, epilepsy meds in PH - (Manila Standard via NewsPoints Desk)

  • Novartis' Philippine unit has implemented price cuts of 15% to 61% for hypertension drugs covering Novartis hypertension medicines ranges from 15 to 61 percent, covering valsartan, valsartan/hydrochlorothiazide, valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide, Manila Standard reported Monday.

  • In addition, the prices of the epilepsy drugs carbamazepine and oxcarbazepine were slashed by 10% to 87%.

  • "Novartis is implementing our legacy pricing initiative in the Philippines in line with our shared goal of providing Filipinos with affordable access to sustainable healthcare," remarked Jugo Tsumura, country president and managing director of Novartis Healthcare Philippines.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.